Indoco Remedies is currently trading at Rs. 155.00, up by 5.55 points or 3.71% from its previous closing of Rs. 149.45 on the BSE.
The scrip opened at Rs. 157.55 and has touched a high and low of Rs. 157.55 and Rs. 155.00 respectively.
The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 238.00 on 26-Nov-2018 and a 52 week low of Rs. 133.10 on 11-Oct-2019.
Last one week high and low of the scrip stood at Rs. 157.55 and Rs. 143.10 respectively. The current market cap of the company is Rs. 1377.19 crore.
The promoters holding in the company stood at 58.69%, while Institutions and Non-Institutions held 16.85% and 24.46% respectively.
Indoco Remedies has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its sterile facility (Plant II) and solid dosages facility (Plant III) at Verna, Goa. The inspection was carried out between October 7 to 15, 2019. This was a Pre-Approval Inspection for a sterile injectable product, with 2 observations on Form 483s, which is now concluded as closed.
The inspection classification of this site has been determined as VAI (Voluntary Action Indicated) by the USFDA.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.